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Summary
Objective: To develop calculation models, using Western immunoblot, as a tool for the estimation of proteolytic human aggrecan fragment
identity.
Method: Seven human aggrecan fragments (calibrators), puriﬁed by CsCl gradient centrifugation and identiﬁed by Western immunoblot of
N- and C-terminals, were used to develop calculation models. The models were used for identiﬁcation of unknown aggrecan fragments
each having one of their N- or C-terminals identiﬁed.
Results: The calibrator molecular weights (Mw) from sodium dodecyl sulfate (SDS)-gels (m), the Mw of amino acids (a) and the Mw of their
carbohydrate substitution (g) were expressed as K¼m/(aþ g), or as K¼ 1.085m/(aþ g) when compensation for the G1 domain was required.
Using these models together with average K-values, 12 out of the 17 immuno-detected aggrecan fragments were calculated to a known
protease cleavage site, while ﬁve were identiﬁed to domain levels.
Conclusions: With six neoepitope antibodies together with antibodies against the G1- and G3-domain it was possible to predict the identity of
several proteolytic fragments from different regions within the aggrecan monomer.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Cartilage
Repair
SocietyIntroduction
Aggrecan, collagen and other matrix components provide
cartilage with its unique mechanical properties. The aggre-
can molecule is composed of structurally deﬁned domains
and regions extensively substituted with keratan sulfate
(KS), chondroitin sulfate (CS) and oligosaccharides1.
Aggrecan can be cleaved by proteinases such as ADAMTS
(a disintegrin-like and metalloprotease with thrombospondin
motifs), matrix metalloproteinases (MMPs), calpains, ca-
thepsins and elastase, resulting in at least 20 different
(identiﬁed) cleavage sites2. Depending on the tissue age,
source of the aggrecan molecule and the pathologic condi-
tion, the action of proteinases generates a complex aggre-
can fragmentation pattern3e8. N-terminal sequencing has
been used for identiﬁcation of aggrecan fragments9e12,
but these methods often require larger protein amounts
and several puriﬁcation steps. The introduction of neoepi-
tope antibodies13 has facilitated the identiﬁcation of aggre-
can fragments, but it would require a large number of
speciﬁc antibodies to identify the many different aggrecan
fragments.
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2006.8Here we describe a method where the tentative identiﬁca-
tion of proteolytic aggrecan fragments is aided by using the
fragment gel electrophoresis molecular weights (Mw) and
one identiﬁed terminal end together with calibration models
based on calculations using known (i.e. N- and C-terminally
identiﬁed) aggrecan fragments.
Materials and methods
AGGRECAN PREPARATION
Human osteoarthritis (OA) synovial ﬂuid (SF) and human
OA knee cartilage were collected from several donors8.
From pooled material SF-D1-fractions and cartilage A1D1-
fractions were puriﬁed by CsCl gradient centrifugation, and
MMP-3 or ADAMTS-4 in vitro digestion of cartilage A1D1-
fraction was performed as described previously8. Prior to
deglycosylation and freeze storage of samples, glycosami-
noglycan (GAG) and protein concentrations were analysed8.
WESTERN IMMUNOBLOT
After loading 2e5 mg GAG per lane of deglycosylated and
reduced samples on 3e8% Tris-acetate (TA) gels, the so-
dium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) was run under reducing conditions8. Mw
markers of 10e250 kDa (Precision Plus Protein Standards,
BioRad) and of 400 kDa (reduced laminin from mouse
Engelbreth-Holm-Swarm Sarcoma, Roche) were used for
Mw calculations. Western immunoblot with different anti-
bodies was performed as described elsewhere8, using anti-
ARGS (mab OA-1) at 5.3 mg/ml (1:2000 dilution), anti-KEEE98
899Osteoarthritis and Cartilage Vol. 14, No. 9at 1:2000 dilution, anti-G3 at 1:500 dilution, anti-G1 at 1:2000
dilution andanti-FFGVat 1:2000dilution, togetherwith perox-
idase conjugated antibodies; goat anti-rabbit IgG at 1:75,000
to 1:400,000 dilution and goat anti-mouse IgG at 20 ng/ml
(1:25,000 dilution). After ECL incubation the results were
visualized on ﬁlm.
CALCULATIONS ON CARBOHYDRATE SUBSTITUTIONS
Using published values for carbohydrate substitu-
tions14e16, estimated amino acid substitutions in human de-
glycosylated aggrecan polypeptides (mature sequence17
starting with N-1VETS-) were used as shown in Table I.
Carbohydrate substitution in the interglobular domain
(IGD) was only counted in fragments lacking the GAG-
enriched regions (e.g. G1-TEGE373, G1-G2). The ExPA-
SyeGlycanMass program (www.expasy.org/tools) was
used for the Mw calculations of KS-stubs (GalNAc1Glc-
NAc1Gal2NeuAc1, 1.04 kDa); O-linked oligosaccharides
(GalNAc1GlcNAc1Gal2NeuAc2, 1.33 kDa); CS-stubs (Xyl1-
Gal2GlcUA2GalNAc1(SO4)1, 1.11 kDa), and N-linked oligo-
saccharides (GlcNAc5Man4Gal3NeuAc3, 3.03 kDa). An
average of 1.2 kDa per substitution was used for the calcu-
lations in the KS-domain (KS-stubs and O-linked oligosac-
charides), and in the CS-domain (CS-stubs and O-linked
oligosaccharides).
Results
AGGRECAN FRAGMENTS DETECTED BY WESTERN
IMMUNOBLOT
Figure 1 shows Western immunoblots of aggrecan frag-
ments from human OA SF [Fig. 1(A)] and from human OA
cartilage [Fig. 1(B and C)]. The antibodies detected approx-
imately 27 different proteolytic fragments. The G3-antibody
detected ﬁve fragments in the SF-D1 sample [Fig. 1(A)]. Ex-
cept for the veriﬁed 1920LGQR-G3 fragment8 all the remain-
ing G3-fragments (430, 214, 171 and 137 kDa) have
unidentiﬁed N-terminal ends. The KEEE- and ARGS-anti-
bodies detected in total six fragments in the SF-D1 sample
[Fig. 1(A)]. The G1-KEEE1714 and 342FFGV-KEEE1714 frag-
ments (seen as a double band), and the 374ARGS-SELE1545
fragment have previously been identiﬁed8, while the 124 and
53 kDa -KEEE1714 fragments, and the 144 kDa 374ARGS-
fragment each have a unidentiﬁed terminal end.
Table I
Carbohydrate substitution criteria used for the calculations. The
positions of the carbohydrate substitutions in the different aggrecan
domains, and the Mw of these substitutions (after chondroitinase
ABC, keratanase and keratanase II digestion) used for calculations
in this paper. O-oligo and N-oligo, O- or N-linked oligosaccharides
Domains Substitutions Substitution
positions
Calculated
Mw per
substitution
G1 No e e
IGD* KS (Thr) and
N-oligo (Asn)
Thr352, Thr357,
Thr370 and Asn368
1 kDa (KS),
3 kDa (N-oligo)
G2 No e e
KS KS and O-oligo 80% of Ser and
50% of Thr
1.2 kDa
CS CS and O-oligo 55% of Ser 1.2 kDa
G3 No e e
*The substitution in the IGD was only counted in fragments
lacking the GAG-enriched regions.The high Mw G1- and 342FFGV- fragments detected in
cartilage-A1D1 after MMP digestion clearly reduced to
smaller fragments as seen by the G1- and FFGV-antibody
reactions [Fig. 1(B and C)]. Large fragments such as G1-
G3 and G1-KEEE1714/SELE1545 were all C-terminally
cleaved to smaller fragments where the G1-IPEN341 frag-
ment was the most prominent [Fig. 1(B)]. Several minor
prominent G1-fragments (245, 218, 172 and 134 kDa) with
unidentiﬁed C-terminal ends were also detected in the
MMP digested cartilage sample, indicating a minor cleave
site in addition to the major -N341Y 342F- MMP-site in the
IGD [Fig. 1(B)]. The action of this secondary MMP cleavage
was also seen with the FFGV-antibody [Fig. 1(C)] where the
high Mw 342FFGV- fragments (342FFGV-G3/KEEE1714) were
C-terminally trimmed to smaller 342FFGV- fragments by the
MMP digestion.
Even though some of these immuno-detected aggrecan
fragments in Fig. 1 have previously been N- and C-termi-
nally identiﬁed by Western immunoblot8, most of the im-
muno-detected aggrecan fragments in the SF and in the
cartilage samples (marked by their Mw) have only one ter-
minal end of the fragment veriﬁed, and thus need further
supportive analysis for their identiﬁcation.
DEVELOPMENT OF MODELS USED FOR THE CALCULATION
OF THE AGGRECAN FRAGMENT IDENTITY
To be able to make qualiﬁed estimations of the identity of
aggrecan fragments which have only one of their end termi-
nals identiﬁed (see Fig. 1), calculation models were devel-
oped as follows.
A relationship between the Mw estimated by SDS-PAGE
migration (m-value) and the Mw calculated using the amino
acid sequence (a-value) can be expressed as K¼m/a,
where K is termed calibration constant. Using an average
value of 118.9 Da per amino acid for the a-values, and if
the m-values are expressed in kDa, the K-values are close
to 1.0 for proteins with few or no carbohydrate substitutions.
For example serum albumin has an m-value of 66.5 kDa
(our lab, results not shown) and an a-value of 69.3 kDa giv-
ing K¼ 0.96. For proteoglycans with a high degree of GAG
and oligosaccharide substitutions, the difference between
the m-value and the a-value is large. As an example degly-
cosylated human aggrecan monomers have anm/a quotient
of approximately 1.7.
By Western immunoblots we have N- and C-terminally
identiﬁed seven different aggrecan fragments, here called
calibrators, prepared from adult human OA knee joints8.
Based on the formula K¼m/a, the calibrator’s individual
K-values showed large variations (results not shown).
However, if the Mw for the GAG-stubs remaining after
deglycosylation (the estimated total Mw of GAG-stubs
and oligosaccharides in a sequence; g-value) were in-
cluded in the formula, the individual K-values for the calibra-
tors became homogenous (Table II). This formula, K¼m/
(aþ g), is named model 1.
Large aggrecan G1-fragments such as G1-SELE1545 mi-
grated relatively faster in the SDS-gel compared to the com-
bined migration of G1-TEGE373 and 374ARGS-SELE1545
fragments (Table II). Therefore, the combined PAGE Mw
(m-values) of G1-fragments generated by proteinase cleav-
age in the IGD (e.g. G1-TEGE373 and the adjacent
374ARGS-SELE1545) have an m-value 8.5% (SD¼ 1.8,
n¼ 3) greater than the corresponding uncleaved fragment of
G1-SELE1545 (Table II). For this reason, model 1 (K¼m/
[aþ g]) is not optimal for largeGAG containingG1-fragments.
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Fig. 1. Human aggrecan fragments in SF (A) and in cartilage (B and C) samples were detected by Western immunoblot. The samples were
separated by SDS-PAGE and after transfer to PVDF-membranes probed with different antibodies as shown. Different amount of GAG per lane
and different ﬁlm exposure times were used to facilitate comparisons between the immunobands. Immuno-detected aggrecan fragments hav-
ing only one identiﬁed terminal end are marked by their Mw values (in kDa), while fragments marked by amino acids (or marked by a domain)
have veriﬁed N- and C-terminal ends. The fragment marked # (B) has been identiﬁed as the deglycosylation enzyme chondroitinase ABC
(results not shown). SF, synovial ﬂuid D1-fraction; C, cartilage A1D1-fraction; C-MMP, MMP-3 in vitro digested cartilage. The positions of
Mw markers are indicated (in kDa) in the ﬁgures.A model 2 (K¼ 1.085m/[aþ g]) was therefore used to com-
pensate for theG1-domainby increasing them-valueby8.5%.
Model 1 was thus found suitable for calculating large
aggrecan fragments containing GAG-enriched regions lacking
the G1-domain (e.g. 374ARGS-SELE1545), or for smaller G1-
fragments lacking the KS- and CS-domains (e.g. G1-
TEGE373),whilemodel2wasbestsuited for largeG1-fragments
containing the GAG-enriched regions, such as G1-SELE1545.
The calibration constants in Table II were derived from
known proteolytic fragments. In order to generate calibration
constants that could be used to identify additional fragments
and regions within the aggrecan molecule, the calibrators
were divided into group A and B depending on their K-values
(Table II), and averageK-values (KA andKB) were calculatedfor each group. The mean calibration constant KA (1.2604,
SD¼ 0.0085) was found to be suitable for calculation of ag-
grecan fragment G1-SELE1545, and all smaller fragments
within this sequence (e.g. G1-TEGE373 and 374ARGS-
SELE1545). The mean calibration constant KB (1.1709,
SD¼ 0.0085) was suitable for calculation of all other aggre-
can fragments such as polypeptides with a C-terminal
of -KEEE1714 or further downstream (e.g. G1/342FFGV-
KEEE1714/TAQE1819/G3), and for fragments within the CS-
2 domain which have an N-terminal at 1546GRGT- or further
downstream (e.g. 1546GRGT/1715GLGS-LGQR1920/G3).
Comparing a theoreticalm-value (calculated from themodels
and calibration constants) with the m-values from PAGE,
suggested an accuracy of 99e99.8% for the calibrators.
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Fig. 1. (continued)ESTIMATING THE IDENTITY OF AGGRECAN FRAGMENTS
BY USING THE CALCULATION MODELS
Seventeen aggrecan fragments which had only one identi-
ﬁed terminal end (by Western immunoblot) are shown in
Fig. 1. To estimate their unknown opposite terminal end, cal-
culations using the two models were conducted (Table III).
For 10 of these fragments (sequence size between 160 and
1200 amino acids) the calculated N- or C-terminal was 25
amino acids from a known proteinase cleavage site, and for
six of these fragments this difference was 5 amino acids
(Table III). The 198, 218 and 245 kDa G1-fragments, and
the 150 and 168 kDa 342FFGV- fragments, together with
the144 kDa 374ARGS- fragment had their calculatedC-termi-
nal ends within the minor MMP cleavage region11 -GVG/
ED933e1352Y 934e1353L/ISGL-. The 124 kDa -KEEE1714 frag-
ment had a suggested N-terminal in the same minor MMP
cleavage region (Table III).
The 292 kDa 342FFGV- fragment had its C-terminal end
calculated as -LPSG1478, suggesting a cleavage in the mul-
tiple m-calpain site18 -XDLS1334e1453Y 1335e1454GLPS-. The53 kDa -KEEE1714 fragment and the 214 kDa G3-fragment
both had a suggested N-terminal at 1546GRGT-, indicating
an aggrecanase cleavage at -SELE1545Y 1546GRGT-. The
G3-fragments of 137 and 171 kDa had suggested N-termi-
nals at the aggrecanase cleavage sites -TAQE1819Y 1820A-
GEG- and -KEEE1714Y 1715GLGS-, respectively.
The G3-fragment of 430 kDa, the G1-fragments of 134
and 172 kDa, together with the 342FFGV- fragments of 77
and 125 kDa, had their unknown terminals calculated to po-
sitions with no known proteolytic cleavage site, and there-
fore these fragments could only be veriﬁed at domain
levels (Table III).
Discussion
The linear migration of polypeptides in SDS-gels played
a critical role in the calculation experiments presented
here. The 3e8% TA gels, linear between 30 and 400 kDa,
were used since several of the proteolytic aggrecan frag-
ments have an Mw> 300 kDa.
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Fig. 1. (continued)The deglycosylation efﬁcacy of proteins containing GAG
chains also inﬂuences the migration rates in the SDS-
PAGE. We found that for human aggrecan fragments, a de-
glycosylation using 1 mU chondroitinase ABC and 1 mU
keratanase and 0.1 mU keratanase II per mg GAG, resulted
in a clear and sharp fragmentation pattern in the SDS-gels
with no further change in migration with higher enzyme to
substrate ratios (results not shown).
When developing the models, several different carbohy-
drate substitution criteria were tested. Some of these had
higher substitution grade or a more detailed position of
the substitutions, while other criteria had very few or no sub-
stitutions at all. The calibrators were tested for accuracy,
comparing theoretical M-values with the actual m-values
from PAGE, using the different substitution criteria. Thecriteria with the best accuracy were selected and are pre-
sented in Table I. One feature of these criteria was that
the IGD carbohydrate substitutions (g-value) were only
counted in the G1-TEGE373 calibrator. If excluding this
g-value from the G1-TEGE373 calibrator then its K-value dif-
fered strikingly from the K-values of the G1-IPEN341 calibra-
tor (lacking IGD carbohydrate substitutions) and from the
K-values of the other calibrators in group A (Table II).
Similarly, if the g-value in the IGD was calculated for large
fragments containing the GAG-enriched regions (e.g. G1-
SELE1545/KEEE1714) then their K-values would also be out-
lying. Even though most of the calibrators were created by
ADAMTS or MMP in vitro digestion of cartilage-A1D1, these
fragments are also found in low quantities in vivo8. While
G1-TEGE373 fragments originate from larger fragments
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N- and C-terminally identified aggrecan fragments (calibrators). Western immunoblot identified aggrecan fragments from human OA knee
joints8 were grouped and their calibration constants (K ) were calculated using model 1 (K¼m/[aþ g]) or model 2 (K¼ 1.085m/[aþ g]).
Mw values are expressed in kDa. A1D1-MMP and A1D1-TS4; MMP-3 or ADAMTS-4 in vitro digested cartilage. SF-D1; synovial fluid D1-
fraction
Source *m-Value (SD, n) ya-Value zg-Value Model K
Group-A calibrators
G1-IPEN341 A1D1-MMP 51 (1, 11) 40.54 0 1 1.2580
G1-TEGE373 A1D1-TS4 64 (2, 12) 44.35 6 1 1.2711
342FFGV-SELE1545 SF-D1 310 (9, 8) 143.15 105.12 1 1.2486
374ARGS-SELE1545 A1D1-TS4 309 (12, 10) 139.35 105.12 1 1.2634
G1-SELE1545 A1D1-TS4 337 (14, 9) 183.70 105.12 2 1.2660
G1-IPEN341þ 342FFGV-SELE1545 e 361 183.70 105.12 1 1.2499
G1-TEGE373þ 374ARGS-SELE1545 e 373 183.70 111.12 1 1.2652
Group-B calibrators
342FFGV-KEEE1714 SF-D1 337 (12, 7) 163.25 126.9 1 1.1615
G1-KEEE1714 A1D1-TS4 359 (15, 7) 203.79 126.9 2 1.1779
G1-IPEN341þ 342FFGV-KEEE1714 e 388 203.79 126.9 1 1.1733
*Mean Mw from PAGE migration.
yCalculated Mw from the amino acid sequence.
zCalculated Mw of the GAG-stubs and oligosaccharides according to the substitution criteria in Table I.which have carbohydrate substitutions in the IGD (known to
be important for the aggrecanolysis in the IGD19,20) it is pos-
sible that the reason why some large G1-fragments, such
as G1-SELE1545, can be found in SF is their lack of these
carbohydrate substitutions.
Some of the fragments in Table III had a calculated amino
acid end far from (>25 amino acids) a known proteolytic
cleavage site. The reason for this could be that in the calcu-
lated regions these putative cleavage sites have not been
veriﬁed. Another explanation is that an exopeptidase activ-
ity has shortened these aggrecan polypeptides. Such exo-
peptidase activity has been shown for cathepsin-B in the
IGD where it at acidic pH acts as a carboxypeptidase21. A
third reason why a proteolytic fragment’s proposed termina-
tion is not a recognized cleavage site could be that the
model and/or calibration constant are not suitable for the
calculated region.The 77 kDa 342FFGV- fragment and the 134 kDa G1-frag-
ment had a proposed C-terminal in the KS-domain, although
it is possible that an MMP cleavage between the KS- and
CS1-domains22 (-P829 | 832T-) or an m-calpain cleavage18
at -PGVA690Y 691AVPV- generated these fragments.
The 53 kDa -KEEE1714 fragment and the 214 kDa G3-
fragment had their N-terminals calculated to 1531TLVE-
and 1521GFPT-, respectively [Fig. 1(A), Table III]. Even
though we cannot rule out that these fragments could have
N-terminals starting with 1525VDST-, from a cathepsin-D
cut23 at -TVSL1524Y 1525VDST-, it is more likely that these
fragments have N-terminals starting with 1546GRGT-, since
OA knee joints contain the -SELE1545 fragment3,8 indicative
of ADAMTS cleavage at the -SELE1545Y 1546GRGT- site in
these joints.
Similarly, the 137 and 171 kDa G3-fragments with
calculated N-terminals of 1782SLPS- and 1669PGFS-,Table III
Calculated identification of aggrecan fragments. Aggrecan fragments from human OA knee joints which have one amino acid terminal iden-
tified by Western immunoblot (see Fig. 1) were calculated, and their unknown opposite terminals were estimated using the models and mean
calibration constants. Proposed identities of the aggrecan fragments are shown. A1D1; cartilage A1D1-fraction, A1D1-MMP; MMP-3 in vitro
digested cartilage, and SF-D1; synovial ﬂuid D1-fraction
Western blot identiﬁed end Source *m-Value (SD, n) yModel 1 or 2 (KA or KB) Calculated terminal Proposed identity
G1- A1D1-MMP 134 (8, 7) 2 (KA) -PSEE
778 G1-KS
G1- A1D1-MMP 172 (5, 7) 2 (KA) -TSTV
888 G1-CS1
G1- A1D1 198 (3, 5) 2 (KA) -VEDI
991 G1-GVED990
G1- A1D1 218 (4, 6) 2 (KA) -AAPG
1082 G1-GVED1085
G1- A1D1-MMP 245 (5, 5) 2 (KA) -SGLP
1204 G1-GVED1199
342FFGV- A1D1-MMP 77 (2, 15) 1 (KA) -LPTW
741 342FFGV-KS
342FFGV- A1D1-MMP 125 (3, 15) 1 (KA) -GDVS
857 342FFGV-CS1
342FFGV- A1D1-MMP 150 (4, 8) 1 (KA) -SGLP
938 342FFGV-GVGD933
342FFGV- A1D1-MMP 168 (5, 15) 1 (KA) -VEDI
1010 342FFGV-GVED1009
342FFGV- A1D1-MMP 292 (11, 15) 1 (KA) -LPSG
1478 342FFGV-EDLS1453
374ARGS- SF-D1 144 (7, 11) 1 (KA) -GDLS
935 374ARGS-GVGD933
-KEEE1714 SF-D1 53 (3, 5) 1 (KB)
1531TLVE- 1546GRGT-KEEE1714
-KEEE1714 SF-D1 124 (3, 5) 1 (KB)
1280PSGE- 1257ISGL-KEEE1714
-G3 SF-D1 137 (1, 5) 1 (KB)
1782SLPS- 1820AGEG-G3
-G3 SF-D1 171 (2, 5) 1 (KB)
1669PGFS- 1715GLGS-G3
-G3 SF-D1 214 (4, 5) 1 (KB)
1521GFPT- 1546GRGT-G3
-G3 SF-D1 430 (23, 5) 2 (KB)
568EQFT- G1-G3
*Mean Mw in kDa from PAGE migration.
yModel 1, K¼m/(aþ g); Model 2, K¼ 1.085m/(aþ g); KA¼ 1.2604 and KB¼ 1.1709.
904 A. Struglics et al.: Aggrecan fragments in Western immunoblotrespectively, could have their N-terminals generated by
the cathepsin-D cleavage23, although since the OA-joints
have ADAMTS cleavage in the CS-2 regions generating
-SELE1545, -KEEE1714 and -TAQE1819 fragments3,8,24 we
propose that the 137 and 171 kDa G3-fragments have ag-
grecanase generated N-terminals of 1820AGEG- and
1715GLGS-, respectively [Fig. 1(A), Table III].
Three distinct immunobands of 214, 171 and 137 kDa
were detected by the anti-G3 antibody in the SF-D1 sample
[Fig. 1(A)]. Similar anti-G3 immuno patterns in human OA-
SF samples have been described3, and the authors sug-
gested the same N-terminals for these G3-fragments as
was indicated by our model calculations (Table III).
The models together with the calibration constant KB
were used for calculations in the CS-2 region at
1715GLGS- and further downstream to the G3-domain. How-
ever, since we have no calibrators in these parts of the mol-
ecule the models and calibration constants presented have
not yet been proven for this region of the aggrecan mole-
cule. The 430 kDa G3-fragment detected in SF-D1 sample
is most likely the aggrecan monomer [Fig. 1(A)]. Due to
the low content of these fragments in SF, we were not
able to verify the N-terminal using G1-antibodies (results
not shown). Although, a similar (429 kDa) G1-G3 fragment
in the human cartilage A1D1-fraction has been, by Western
immunoblot, N- and C-terminally veriﬁed (results not
shown). The calculated theoretical m-value, using KB and
model 2, for the human aggrecan monomer is 503 kDa.
The discrepancy between the theoretical and actual
m-values for the G1-G3 fragment is most likely due to
non-linearity of the 3e8% TA SDS-gels at Mw above
400 kDa, resulting in a PAGE Mw underestimation, but
the discrepancy could also be explained to the lack of
good models and calibrator constants for the G3 domain
and/or the entire monomer.
In summary, we have shown that by using neoepitope an-
tibodies speciﬁc for some selected aggrecan cleavage sites
together with G1- and G3-antibodies it is possible to esti-
mate by calculation the probable identity of a range of ag-
grecan fragments which in the absence of a whole range
of neoepitope antibodies otherwise can only be approxi-
mated. When using the SDS-PAGE within its linear range
the calculation models together with the calibration con-
stants work well for the human aggrecan N-terminal region
reaching into the CS-2 domain of the aggrecan core protein.
The C-terminal domain of the aggrecan molecule may need
a more reﬁned model with a speciﬁc calibration constant.
This calculation method may be further adjusted for use
with aggrecan and proteoglycan molecules from other tis-
sues and species, or when using different deglycosylation
conditions and PAGE-systems. Six out of the eight anti-
bodies that we used are commercially available (www.bio-
compare.com), which facilitate the creation of additional
model systems.
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